NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) platform technology to treat endourological conditions, announced the three-year outcomes data from the Rezūm II pivotal clinical trial of its minimally invasive Rezūm® System, demonstrating significant, effective and durable lower urinary tract symptom (LUTS) relief, improved quality of life and preserved sexual function for men treated for benign prostatic hyperplasia (BPH). The outcomes were recently published in the January 2018 issue of Urology.
